NSCLC – Non small cell lungcarcinoma
Introduction
The update of the S3 guideline Prevention, Diagnostics, Therapy and After-Care of lung carcinomas, published in the year 2018, comments as follows on the PD-L1 testing:
“Testing for PD-L1 expression“
“In NSCLC, a correlation between the PD-L1 expression detected in immunohistochemistry and the reaction to a therapy with monoclonal antibodies aimed against PD-1 or PD-L1 has been proven in various studies. For this reason, immunohistochemical examinations are to be carried out on the question of a PD-L1 expression and the outcome stated as a percentage of tumor cells positive in the membrane (proportion score).
Data protection and the German Drug Advertising Act (HWG) require that the professional affiliation of the portal visitors. The complete page with all contents is only available to medical personnel.
You can login with DocCheck, you QuIP-Account or Access-Code.
Login with QuIP-Account
Please enter your user name (e-mail address) and the corresponding password, which you also need for your login to the ring trial portal www.quip.eu can be used.
Login with Access-Code
Please enter your personal code, which you have already received by voucher.